U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H13NO3.C4H11NO3
Molecular Weight 376.4037
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of KETOROLAC TROMETHAMINE, (S)-

SMILES

NC(CO)(CO)CO.OC(=O)[C@H]1CCN2C1=CC=C2C(=O)C3=CC=CC=C3

InChI

InChIKey=BWHLPLXXIDYSNW-MERQFXBCSA-N
InChI=1S/C15H13NO3.C4H11NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13;5-4(1-6,2-7)3-8/h1-7,11H,8-9H2,(H,18,19);6-8H,1-3,5H2/t11-;/m0./s1

HIDE SMILES / InChI
Molecular Formula C4H11NO3
Molecular Weight 121.135
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C15H13NO3
Molecular Weight 255.2686
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

(S)-ketorolac is the enantiomer of ketorolac, a nonsteroidal anti-inflammatory drug. (S)-ketorolac exhibited potent cyclooxygenase (COX1 and COX2) enzyme inhibition. (S)-ketorolac is considered to be active enantiomer of racemic ketorolac.

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 0.46 µM [IC50]
Inhibitor
8297
 1.46 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Preclinical
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Absolute configuration of (-)-5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2-alpha]pyrrole-1-carboxylic acid, the active enantiomer of ketorolac.
1986 Apr
The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate.
1994 Jan
Preclinical enantioselective pharmacology of (R)- and (S)- ketorolac.
1998 Feb
Inhibition of anandamide hydrolysis by the enantiomers of ibuprofen, ketorolac, and flurbiprofen.
1999 Feb 15
Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX1- and COX2-inhibitors in nerve-injured rats.
1999 Jul
Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics.
2017 Sep

Sample Use Guides

In Vivo Use Guide
rats: 0.01–1 mg/kg s.c.
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:53:33 GMT 2023
Edited
by admin
on Sat Dec 16 10:53:33 GMT 2023
Record UNII
E84R314D35
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
KETOROLAC TROMETHAMINE, (S)-
Common Name English
1,3-PROPANEDIOL, 2-AMINO-2-(HYDROXYMETHYL)-, (1S)-5-BENZOYL-2,3-DIHYDRO-1H-PYRROLIZINE-1-CARBOXYLATE (SALT)
Common Name English
1H-PYRROLIZINE-1-CARBOXYLIC ACID, 5-BENZOYL-2,3-DIHYDRO-, (1S)-, COMPD. WITH 2-AMINO-2-(HYDROXYMETHYL)-1,3-PROPANEDIOL (1:1)
Systematic Name English
Code System Code Type Description
FDA UNII
E84R314D35
Created by admin on Sat Dec 16 10:53:33 GMT 2023 , Edited by admin on Sat Dec 16 10:53:33 GMT 2023
PRIMARY
CAS
156699-13-7
Created by admin on Sat Dec 16 10:53:33 GMT 2023 , Edited by admin on Sat Dec 16 10:53:33 GMT 2023
PRIMARY
PUBCHEM
73416230
Created by admin on Sat Dec 16 10:53:33 GMT 2023 , Edited by admin on Sat Dec 16 10:53:33 GMT 2023
PRIMARY
Related Record Type Details
Structure of KETOROLAC TROMETHAMINE
RACEMATE -> ENANTIOMER
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966